## Why consider involving paediatric networks when preparing the PIP?

## Q31. Why should I consider involving paediatric networks when preparing the PIP? New January 2014

A30. The European Network for Paediatric Research at the European Medicines Agency (EnprEMA) provides a point of contact for a number of specialty and multi-specialty networks. Early involvement of clinical research networks may help to develop a PIP in a number of ways, and should be considered when preparing the application. Areas of expertise that can be offered by Enpr-EMA members are reported in the Enpr-EMA database  $^{\Box}$ .

Networks may provide assistance in the following areas: identification of existing databases, location of study sites and investigators to conduct natural history studies, access to clinicians who can provide data about patient throughput or develop bespoke feasibility assessments, definition of important paediatric needs, priorities and relevant outcomes, identification of acceptable trial procedures / visit schedules, and clarification of other scientific questions.

- Feedback from the networks
- Implications and action points for Enpr-EMA

